NCT00195195
Completed
Not Applicable
A Rapamune Follow-up Registry in Transplant Recipients in the Nordic Countries, "Wrap-up"
Wyeth is now a wholly owned subsidiary of Pfizer0 sites66 target enrollmentJanuary 2005
Overview
- Phase
- Not Applicable
- Intervention
- Sirolimus
- Conditions
- Transplantation
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Enrollment
- 66
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Transplantation patients treated with sirolimus (Rapamune).
Exclusion Criteria
- •Patients must be able to give informed consent.
Arms & Interventions
1
Sirolimus
Intervention: Sirolimus
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of KidneysKidney Transplantation in Highly Sensitized PatientsNCT05714514Hansa Biopharma AB64
Completed
Not Applicable
Heart Transplant Registry of VárosmajorDisorder Related to Cardiac TransplantationNCT02347371Semmelweis University Heart and Vascular Center11
Recruiting
Not Applicable
Long-Term Follow-Up of Recipient of Gene Transfer ResearchRetroviridae InfectionsCancerNCT01492036M.D. Anderson Cancer Center130
Completed
Not Applicable
Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In HypercholesterolaemiaHypercholesterolaemiaNCT01352897AstraZeneca800
Completed
Not Applicable
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein OcclusionRetinal Vein OcclusionMacular OedemaNCT01566526Allergan26